Q4 2024 Management View CEO Brian Lian highlighted 2024 as an exceptionally busy year, with successful results from four studies, including the Phase 2 VENTURE trial for subcutaneous VK2735, which ...

However, this ruling does not impact the company's ongoing clinical formulations. Although Atossa believes there are appealable issues, it has decided against pursuing an appeal due to the ...

The expansion is a natural progression for Upperton who already develops and manufactures small molecule and biological, ...

"Prior 28-day Phase 1 data demonstrated encouraging tolerability with the tablet formulation, as well as promising reductions in body weight. We believe VK2735's clinical results to-date suggest a ...

The ALIVE clinical trial, conducted in Ethiopia ... "With its child-friendly formulation—orodispersable and mango-flavored—and its high acceptance, this tablet holds great potential for ...

Jupiter Neurosciences Inc., a clinical-stage pharmaceutical company developing JOTROL, a patented resveratrol-based platform, ...